Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is one of the best drug stocks to buy according to analysts.
Kiniksa Pharmaceuticals International Plc (KNSA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 2,976 | $222,039 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.24 | 235,019 | $4,520,942.99 | 843,352 | 2018-05-29 | Filing | |
| $20.91 | 25,000 | $522,747.50 | 608,333 | 2018-05-29 | Filing | |
| $19.81 | 250,000 | $4,953,150.00 | 583,333 | 2018-05-29 | Filing | |
| $18.00 | 333,333 | $5,999,994.00 | 333,333 | 2018-05-29 | Filing | |
| $18.00 | 69,444 | $1,249,992.00 | 900,443 | 2018-05-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $81.43 | 3,673 | $299,092.39 | 11,672 | 2026-07-29 | Filing | |
| $54.04 | 21,097 | $1,140,081.88 | 65,623 | 2026-05-01 | Filing | |
| $53.52 | 37,327 | $1,997,741.04 | 86,720 | 2026-05-01 | Filing | |
| $54.02 | 48,565 | $2,623,481.30 | 0 | 2026-05-01 | Filing | |
| $54.01 | 2,141 | $115,635.41 | 0 | 2026-04-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 202,021 | $15,072,787 | 2.23% | |
| 2. | 54,401 | $4,058,859 | 0.32% | |
| 3. | 40,907 | $3,052,071 | 0.03% | |
| 4. | 40,735 | $3,039,238 | 0.1% | |
| 5. | 34,341 | $2,562,182 | 0.48% |
News See All
9 Best Drug Stocks to Buy According to Analysts
In this article, we will look at the 9 Best Drug Stocks to Buy According to Analysts.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript February 24, 2026Kiniksa Pharmaceuticals, Ltd. misses on earnings expectations.
Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is one of the most promising mid-cap healthcare stocks under $50.
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2025 Earnings Call Transcript October 28, 2025 Operator: Thank you for standing by.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q2 2025 Earnings Call Transcript July 29, 2025Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $0.18.
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2025 Earnings Call Transcript April 29, 2025Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is $0.11, expectations were $0.02.
10 Best UK Growth Stocks to Buy Now
This article looks at the best UK growth stocks to buy now. The start of this year has marked interesting developments for the UK market.
12 Best Small Cap Pharma Stocks to Buy Now
In this article, we will be talking about the 12 best small cap pharma stocks to buy now.
Hedge Fund Resource Center